Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,304.00
Bid: 12,304.00
Ask: 12,306.00
Change: 186.00 (1.53%)
Spread: 2.00 (0.016%)
Open: 12,244.00
High: 12,384.00
Low: 12,228.00
Prev. Close: 12,118.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Stocks lack direction amid quiet start to week

Mon, 19th Feb 2024 11:51

(Alliance News) - Stock prices in London lacked direction at midday Monday, amid a quiet start to the week.

On Tuesday, markets in New York will reopen, after being closed for the Washington's Birthday public holiday on Monday.

The FTSE 100 index was up 8.27 points, 0.1%, at 7,719.98. The FTSE 250 was down 41.39 points, 0.2%, at 19,150.54, and the AIM All-Share was down 2.80 points, 0.4%, at 755.98.

The Cboe UK 100 was up 0.1% at 772.65, the Cboe UK 250 was down 0.2% at 16,569.84, and the Cboe Small Companies was up 0.2% at 14,519.33.

In European equities on Monday, the CAC 40 in Paris and the DAX 40 in Frankfurt were both down 0.4%.

"The FTSE 100 made a sluggish start to trading on Monday, lacking some direction amid the absence of big corporate or economic releases," said AJ Bell investment director Russ Mould.

"That changes later in the week when the minutes of the latest Federal Reserve meeting are released and the AI stock Nvidia unveils its latest quarterly results. There is little margin for error for the chip specialist given the supercharged surge in its share price which has continued into 2024."

New data on Monday showed that the average price tag on a UK home jumped by more than GBP3,000 month-on-month in February, according to a property website.

Across Britain, the average new seller asking price increased by 0.9% or GBP3,091 this month to GBP362,839, Rightmove said. The website said the increase is in line with the seasonal rise it would expect in February.

In signs of growing market momentum, the average asking price is also up by 0.1% compared with a year earlier, following a period of annual falls in every month since August 2023.

The number of sales agreed in the first six weeks of this year is also 16% higher than in the same period last year, Rightmove said.

On the back of the data, London's housebuilders were trading lower. Taylor Wimpey lost 0.3%, Persimmon was down 0.8% and Barratt Developments fell by 0.2%.

Elsewhere in the FTSE 100, AstraZeneca jumped 3.5%.

The Cambridge-based pharmaceutical company reported positive analysis from its Laura phase III trial for Tagrisso in lung cancer.

The treatment, following chemoradiotherapy, showed a "meaningful improvement in progression-free survival" for a group of sufferers of non-small cell lung cancer, versus those in the placebo group.

Overall survival data showed a "favourable trend" for Tagrisso, but Astra noted the data "were not mature" at the time of the analysis. The trial will continue to assess overall survival as a secondary endpoint.

Separately, the firm announced Tagrisso with chemotherapy received US approval from the Food & Drug Administration for use in locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.

In the FTSE 250, Currys PLC shares jumped 33% to 62.50 pence, with Chinese e-commerce firm JD.com Inc the latest to throw its hat in the ring for a possible takeover of the consumer electronics retailer.

JD.com, noting press coverage, said it is mulling an acquisition of Currys. The Telegraph newspaper on Sunday reported JD.com has held early talks with Currys.

JD.com noted that there is no certainty that its interest will result in a bid.

On Sunday, Currys said it rejected a takeover tilt from US private equity firm Elliott Investment Management LP.

Currys said it received an unsolicited proposal worth around GBP702.8 million from Elliott, or 62 pence per share. The Currys market value of GBP708.7 million topped that figure on Monday.

Currys said the Elliott bid "significantly undervalued the company and its future prospects".

Bank of Georgia rose 5.0%, after it snapped up Armenia's Ameriabank.

Following last week's announcement that it was in talks with Ameriabank regarding a potential acquisition, Bank of Georgia confirmed the signing of a conditional agreement to acquire the leading Armenian bank for USD303.6 million.

Bank of Georgia said that the Yerevan-based bank has "an attractive franchise, in an attractive market, with similar characteristics to Georgia".

Bank of Georgia Chair Mel Carvill said: "This transaction is a significant milestone for the group and a new chapter in our strategic development. Through Ameriabank we are set to enter Armenia, one of the fastest-growing economies in the region. Ameriabank has a well-regarded and experienced management team, and I am delighted that they will stay on after the transaction is closed. "

The pound was quoted at USD1.2618 at midday on Monday in London, higher compared to USD1.2582 at the equities close on Friday. The euro stood at USD1.0775, unchanged from late Friday. Against the yen, the dollar was trading at JPY149.97, down compared to JPY150.13.

Brent oil was quoted at USD82.77 a barrel at midday in London on Monday, down from USD82.88 late Friday. Gold was quoted at USD2,018.88 an ounce, up against USD2,009.01.

By Sophie Rose, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
Today 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
Today 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.